ESTRO 37 Abstract book

S126

ESTRO 37

projects. Moreover, I am strongly convinced that be in contact with researcher form different Institutions and share different ideas is right way to work. Finally, as Medical Physics Expert I strongly agree with the view coming out form last ESTRO meeting (ESTRO36, 2017 Vienna) where both clinical and research character of Medical Physicist should be improved and strengthen for each professional [1]. I had to work on a new project in a Medical Physics field also almost new for me. Unlike other times where I already knew the field of research, this time I was disoriented by the new field of the project. Therefore my first aim in participating to the ESTRO Research Master Class was to improve my project and get in contact to some people expert in the specific field. The abstract and project writing phase was already for me an opportunity to go deeply inside the field and strength the project idea, focusing on the main objective and describing the technique that I would like to apply. I was accepted to the Master Class (ESTRO Research Master Class, 10-13 September 2017, Florence, Italy). That was a great experience, and we had talks on different tasks, valuable debate in small group on each single project, personal discussion with teachers and opportunity to share experience and compare projects/ideas with different colleagues both young investigators as well as well experienced researchers. I participated to the Master Class with a first aim to strength my project idea, but then I come back realizing that the most valuable part of the Master Class was the possibility to get in contact with different professionals and share ideas. The opportunity to talk with great investigators in a friendly and relaxed atmosphere I think is one of the most valuable points. Also all coffee breaks, lunches, dinners and also social life together was an opportunity to share ideas and construct a friendly and relaxed atmosphere. I came back not only with a stronger project idea, but also (and more important) with a robust and valuable method to do research and with lots of contact of people interested to collaborate with each other around world. [1] Bortfeld T., Torresin A., Fiorino C. et al. The research versus clinical service role of medical physics. Radiother Oncol(2015);114(3):285-8 Abstract text My first participation to an ESTRO meeting was in 2005, and my first contact with some of the ESTRO teachers was during the Target Volume Delineation course in Beijing in 2008. I participated to this course during my last year of residency, and it was completely crazy to have, by chance, the possibility to share some drinks with the big names of European radiotherapy while they discussed about the future of our discipline and their vision of ESTRO. This is the beginning of my history in ESTRO, initially as participant to the ESTRO courses and meetings, then as ESTRO fellow in 2010, and now as part of the teaching group. In these almost 10 years, I have been involved in the first Young ESTRO taskforce, in the 3rd AGORA Meeting, in the FALCON program and in the Evidence Based Radiotherapy course. The professional impact of these opportunities is clear and noteworthy. The possibility of sharing my ideas, my doubts, my research and teaching projects with all the ESTRO teachers, usually in a friendly and relaxed atmosphere, boosted my career: it has been easier for me to move my first steps as radiation oncologist as I found a lot of experienced colleagues who helped me since the beginning. After each ESTRO event, I came back with a lot of ideas, with a strategy to realize them, and with SP-0250 Experiences from young scientists: Experience from a young ESTRO teacher B. De Bari 1 1 Hôpital Univ. Jean Minjoz CHU Minjoz Jeans & Belfort- Montbéliard Hospital, Radiation Oncology, Besançon, France

many people who were interested in collaborating and/or in developing these ideas with me. Nevertheless, it is the human and personal aspects of this experience that are not so easy to be showed in the daily life, but that did surely impact my point of view about my profession, my relationships with younger and “less young” colleagues and more in general the meaning of my commitment in ESTRO. SP-0251 Experiences from young scientists: Participant ESTRO Clinical Radiobiology Course J.A. Hundvin 1 1 Haukeland University Hospital, Cancer Treatment and Medical Physics, Bergen, Norway Abstract text One of the first courses to be arranged by ESTRO was focused on radiobiology, which illustrates the central role of said field of study. This contribution will be a presentation on experiences from the Clinical Radiobiology course, organized in Budapest, Hungary, in the spring of 2016. Focus will be set on the academic outcome, as well as the learning methods. Also, the social part of the course will be mentioned briefly. PV-0252 Image-guided boost brachytherapy for anal canal cancer: tumour and functional outcome M. Heilmann 1 , R. Schmid 1 , C. Kirisits 1 , D. Berger 1 , N. Nesvacil 1 , R. Pötter 1 , J. Widder 1 , M. Schmid 1 1 Medizinische Universität Wien, Universtitätklinik für Strahlentherapie, Vienna, Austria Purpose or Objective To analyse clinical outcome in a consecutive cohort of patients with anal cancer treated with external beam radiotherapy (EBRT) +/- chemotherapy and image-guided pulse dose rate brachytherapy (BT). Material and Methods All patients with primary squamous cell cancer of the anal canal referred for primary treatment or after incomplete surgical resection (n=9, 17%) from 2000–2017 receiving PDR-BT as boost in curative intent were included in this retrospective analysis. Treatment consisted of EBRT to the small pelvis to 46 Gy, concomitant chemotherapy with MMC and capecitabine or 5-FU, and an image-guided PDR-BT boost to the primary tumour. Eligibility criteria for BT were: Tumour involving less than half of the anal circumference and < 5cm length at presentation. Reported toxicities were scored according to the CTCAEv4. Descriptive statistics and the Kaplan-Meier method were used for analysis. Results In total, 52 patients were included. Median age was 62.4 years (45 – 90) and 46 (88%) patients were female; 11 (21%) had T1, 31 (60%) T2, 9 (17%) T3, and 1 (2%) T4 primaries. Fifteen patients presented with clinically positive lymph nodes. The mean prescribed EBRT dose was 45.5 Gy (± 3.1 Gy), followed by 14.5 Gy (± 2.0 Gy) PDR-BT boost using single- plain implants. Forty-two (81%) of the patients received concomitant chemotherapy. Median overall treatment time was 53 d (42–115). Image guidance for BT was MRI- based in 15 patients (29%) and CT-based in 37 (71%). With a median follow-up time of 36.6 months, two persistent disease, one local recurrence, and one case with distant metastases were observed. There were two (4%) patients suffering necrosis, two (4%) chronic diarrhea, and seven (13%) fecal incontinence, rendering a 19 % gross G3 toxicity rate (n=11 patients). No G4 or G5 toxicities were Poster Viewing : Poster viewing 5: Pelvic brachytherapy